Bob,
Thanks of course, for the link. I finally found it on msg#17188, dated 1/18/06.
For Xoma, the company continues to sign up licenses for its proprietary Bacterial Cell Expression (BCE) technology. Xoma also receives royalties on sales of psoriasis drug Raptiva at Genentech, and will receive royalties on two new products: Genentech's Lucentis (macular degeneration) and UCB's Cimzia (Crohn's disease) once they gain final approval.
It's just that in light of today's event it's hard for me to come to the same conclusion you have, i.e. 'that the zacks report had it pretty much right'. But perhaps, this isn't the report you wanted to cite.
As for the above blurb Cimzia and Lucentis have not yet been approved, and when and if they are approved Xoma only gets a lower single digit royalty, and only about a 5% royalty on raptiva. Indeed, one could argue that in the absence of that information Zacks' praise is a bit misleading.
In any case, this is not what I call exciting news, then or now. |
